Despite promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable opposition from pharmacy benefit managers. The companies are https://margieqgkg391669.thekatyblog.com/40140612/company-s-drug-faces-is-encountering-pbm-challenges-a-look-at-coverage-disputes